Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program Open Access Alopecia ...
As advances in biomarker testing and the introduction of HER2-targeted therapies transform care for patients with NSCLC, your role as an advanced practice provider also advances. Explore this program ...
As advances in biomarker testing and the introduction of HER2-targeted therapies transform care for patients with NSCLC, your role as an advanced practice provider also advances. Explore this program ...
How can your team use biomarkers to improve diagnosis and management of AD? Explore using biomarker testing to interpret results and guide treatment strategies with an interactive patient simulation, ...
Understanding the indicators of disease progression in CTCL is essential to optimize outcomes and prevent unnecessary disease burden. Join leading experts as they explore the latest evidence and ...
These six bite-sized videos will equip you with insights into the pathophysiological processes underlying Lennox–Gastaut syndrome, the burden on patients and caregivers, and opportunities to increase ...
How can your team use biomarkers to improve diagnosis and management of AD? Explore using biomarker testing to interpret results and guide treatment strategies with an interactive patient simulation, ...
As advances in biomarker testing and the introduction of HER2-targeted therapies transform care for patients with NSCLC, your role as an advanced practice provider also advances. Explore this program ...
Unlock your free and exclusive access to all the news and expert commentary from the congress.
Springer Medicine delivers trusted medical education to specialist doctors in easily digestible formats.
Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we ...
Understanding the indicators of disease progression in CTCL is essential to optimize outcomes and prevent unnecessary disease burden. Join leading experts as they explore the latest evidence and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results